TRBJ2-2P: A Potential Drug Target and Biomarker (G28627)

Target Name: TRBJ2-2P

NCBI ID: G28627

TRBJ2-2P

Other Name(s): TRBJ22P | T cell receptor beta joining 2-2P (non-functional)

TRBJ2-2P: A Potential Drug Target and Biomarker

TRBJ2-2P, or tripartin, is a protein that is expressed in various tissues of the brain, including the cerebral cortical cortical layer. It is a member of the TRBJ family of proteins, which are involved in the regulation of microtubules, the fundamental structure of cells. TRBJ2-2P has been shown to play a role in the regulation of brain function, and is potential drug target and biomarker.

The TRBJ2-2P protein is composed of three subunits, each of which consists of a unique protein domain. The N-terminus of the protein contains a region that is involved in the regulation of microtubule dynamics. This region is known as the \"tubulin-binding\" domain, and it is thought to play a role in the interaction between TRBJ2-2P and microtubules. The middle segment of the protein contains a region that is involved in the regulation of actinin cytoskeleton. This region is known as the \"actinin-binding\" domain, and it is thought to play a role in the interaction between TRBJ2-2P and actinin cytoskeleton. The C-terminus of the protein contains a region that is involved in the regulation of the cytoskeleton. This region is known as the \"cytoskeleton-binding\" domain, and it is thought to play a role in the interaction between TRBJ2-2P and cytoskeleton.

TRBJ2-2P has been shown to play a role in the regulation of a variety of cellular processes, including cell division, differentiation, and migration. It has been shown to interact with a variety of different proteins, including microtubules, actinins, and cytoskeleton. These interactions are thought to play a role in the regulation of cellular processes, and may be potential drug targets.

In addition to its potential drug target and biomarker properties, TRBJ2-2P has also been shown to have potential therapeutic applications. For example, TRBJ2-2P has been shown to be downregulated in certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that targeting TRBJ2-2P may be a potential therapeutic approach for these diseases. Additionally, TRBJ2-2P has also been shown to be involved in the regulation of pain perception, and targeting this protein may be a potential approach for the treatment of chronic pain.

In conclusion, TRBJ2-2P is a protein that is expressed in various tissues of the brain and is involved in the regulation of microtubules, actinin cytoskeleton, and cellular processes. It is potential drug target and biomarker, and has been shown to play a role in the regulation of a variety of cellular processes, including cell division, differentiation, and migration. Additionally, TRBJ2-2P has also been shown to have potential therapeutic applications, including the treatment of neurodegenerative diseases and chronic pain. Further research is needed to fully understand the role of TRBJ2-2P in cellular processes and its potential as a drug target and biomarker.

Protein Name: T Cell Receptor Beta Joining 2-2P (non-functional)

The "TRBJ2-2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ2-2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets